← FDA DRUG APPROVALS

FDA NDA · NDA009102

ANTEPAR

Sponsor: GLAXOSMITHKLINE

APPLICATION
NDA009102
TYPE
NDA
ORIGINAL APPROVAL
1957-01-25
LATEST ACTION
1996-04-26
ROUTE
ORAL
DOSAGE FORM
TABLET, SYRUP
MARKETING STATUS
Discontinued

Products

ANTEPARDiscontinued
PIPERAZINE CITRATE EQ 500MG BASE · TABLET · ORAL
ANTEPARDiscontinued
PIPERAZINE CITRATE EQ 500MG BASE/5ML · SYRUP · ORAL

Approval history

1996-04-26Labeling · Supplement 3AP
1957-01-25Type 2 - New Active Ingredient · Original · priorityAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →